ABUS Stock Summary and Trading Ideas (Arbutus Biopharma | NASDAQ:ABUS)

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

What symbol and exchange does Arbutus Biopharma shares trade?

Arbutus Biopharma trades on the NASDAQ stock market under the symbol ABUS.

What is Arbutus Biopharma stock price doing today?

As of July 24, 2026, ABUS stock price declined to $4.38 with 815,904 million shares trading.

What is Arbutus Biopharma's Beta?

ABUS has a beta of 1.18, meaning it tends to be more sensitive to market movements. ABUS has a correlation of 0.13 to the broad based SPY ETF.

How much is Arbutus Biopharma worth?

ABUS has a market cap of $865.22 million. This is considered a Small Cap stock.

How much money does Arbutus Biopharma make?

Last quarter Arbutus Biopharma reported $179 million in Revenue and $.87 earnings per share. This beat revenue expectation by $178 million and exceeded earnings estimates by $.93.

What is the highest and lowest price Arbutus Biopharma traded in the last 3 year period?

In the last 3 years, ABUS traded as high as $5.38 and as low as $1.69.

What are the top ETFs holding Arbutus Biopharma?

The top ETF exchange traded funds that ABUS belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.

Is Arbutus Biopharma (ABUS) a good investment?

ABUS has outperformed the market in the last year with a return of +35.2%, while the SPY ETF gained +17.7%. In the last 3 month period, ABUS beat the market returning +4.3%, while SPY returned +3.8%. However, in the most recent 2 weeks ABUS has underperformed the stock market by returning -8.8%, while SPY returned -2.1%.

What are the support and resistance levels for Arbutus Biopharma (ABUS)?

ABUS support price is $4.33 and resistance is $4.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABUS shares will trade within this expected range on the day.